The FDA has expanded approval for GSK’s vaccine to protect against RSV to include at-risk adults as young as 50. Previously only licensed for use in those 60 and older, Arexvy is now available for younger adults with underlying medical conditions that increase the risk of severe illness from RSV. Experts, including Professor Ann Falsey, emphasize the importance of broadening the benefits of RSV immunization to younger adults with health conditions. CDC recommendations for the vaccine in the 50-59 age group are awaited, and other companies like Pfizer and Moderna are also developing RSV vaccines for different age groups and populations.
Source link
GSK’s RSV vaccine receives expanded FDA approval
